Navigation Links
NeoGenomics to Present at the Noble Financial Equity Conference
Date:8/12/2008

FT. MYERS, Fla., Aug. 12 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) today announced that it will present at the Fourth Annual Noble Financial Equity Conference at 1:30 p.m. (Pacific) on Monday, August 18, 2008 at the Loews Lake Las Vegas Resort, Nevada.

Robert Gasparini, the Company's President and Chief Scientific Officer, and Steven Jones, the Company's Chief Financial Officer, will give a 23-minute presentation regarding NeoGenomics' market positioning, financial performance, and strategic direction. The presentation will be webcast LIVE featuring high-definition, streaming video and PowerPoint slides. Access is available by logging on to the conference website http://www.noblemadmax.com or directly via http://hosted.mediasite.com/hosted4/Viewer/?peid=d1e3b760-7d83-4d0a-86c1- 82908ba4ba0c. In addition, a portal to the webcast will be available in the Investor Relations section of the NeoGenomics' website. It is recommended that interested parties register at least 10 minutes prior to the start of the presentation to ensure timely access to the webcast.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org .

Interested parties can also access additional investor relations material from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at http://www.hawkassociates.com. An investment profile about NeoGenomics may be found at http://www.hawkassociates.com/clients/additional/index.cfm?client_id=10.

About Noble Financial

Noble Financial is a privately-held, full-service capital markets firm driven by what is often overlooked by other firms -- uncovering the value embedded in the orphaned, undiscovered or misunderstood company. The company focuses on converting market inefficiencies into profit opportunities. Noble Financial supports emerging companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble Financial's equity conferences -- 2008 marks their fourth annual -- allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The company has operated for 24 years and has offices in Florida, New York City and Boston.


'/>"/>
SOURCE NeoGenomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
2. NeoGenomics Announces Results for the 3rd Quarter 2007
3. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
4. Smart Balance to Webcast Presentation at Canaccord Adams Global Growth Conference
5. The Quantum Group to Present at the Noble Financial Equity Conference
6. Nautica Malibu Triathlon, Presented By Toyota, Showcases Athleticism, Philanthropy in 22nd Year
7. USA-ONE Interactive Presents a Free Webinar Series Introducing Docuvation – An Online Document Management Solution
8. AMA Foundation Presents $10,000 Scholarships to Promising Medical Students
9. STAAR Surgical to Present at the Noble Financial Equity Conference
10. Signs of Alzheimers disease may be present decades before diagnosis
11. Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... 28, 2017 , ... Guide to FDA and EU Medical Device Regulations: 2017 ... side of the Atlantic devicemakers do business, this fully updated and expanded guide keeps ... addition to the full text of the FDA’s regulations in 21 CFR Parts 800 ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology: